ADMA Biologics Faces Class Action Lawsuit Over Alleged Market Deception
Investors who purchased ADMA Biologics stock between August 9, 2024, and March 25, 2026, face a critical deadline as a class action lawsuit accuses the company of securities law violations. The complaint alleges that the firm artificially inflated its performance through undisclosed transactions and deceptive sales practices.
The DJS Law Group is spearheading the litigation, which centers on alleged breaches of the Securities Exchange Act. According to the complaint, ADMA Biologics misled the market by failing to disclose specific related-party transactions and engaging in channel stuffing to create a false appearance of robust sales activity. These actions reportedly left shareholders with an inaccurate view of the company's financial health throughout the designated class period.
Investors seeking to participate in the recovery effort must act before the August 10, 2026, filing deadline. While the firm is currently seeking lead plaintiffs to represent the class, individual shareholders are not required to hold a leadership role to be eligible for potential financial recovery. Those who suffered losses are encouraged to contact the DJS Law Group to review their legal standing and documentation requirements.
Comments (0)
No comments yet. Be the first!